---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-006270"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:46:33.659733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clene reports FY2022 net loss of $29.9M; highlights positive clinical data in ALS and MS

## Summary
- Net loss $29.9M ($0.46/share) vs $9.7M ($0.16) prior year; cash $23.3M, runway into Q3 2023.
- HEALEY ALS trial: CNM-Au8 associated with 74% lower risk of clinical worsening at 6 months; 98% reduced risk of death/permanent ventilation.
- RESCUE-ALS OLE: significant ALSFRS-R preservation from randomization to 48 weeks (p=0.0159).
- VISIONARY-MS trial: significant improvements in visual evoked potential and MRI measures supporting neuroprotection.
- Plans to meet FDA in Q3 2023 for end-of-Phase 2 meetings for ALS and MS; secured $25M equity facility with Lincoln Park.

## SEC filing metadata
- accession: 0001437749-23-006270
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/0001437749-23-006270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/clnn20221214_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-006270
- JSON: https://secwatch.observer/filing/0001437749-23-006270.json
- Plain text: https://secwatch.observer/filing/0001437749-23-006270.txt

## Key facts
- Earnings Releases
  Clene Inc. reported financial results for full year ended December 31, 2022.
  - Period: full year ended December 31, 2022
  - Result: reported results
  source text: On March 13, 2023, Clene Inc. (the “Company”) issued a press release announcing its full year operating and financial results for its year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774923006270/0001437749-23-006270-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.